grafa.com
Cure8 news brief
AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion - Grafa
Access, cost, and policy
Risankizumab
Upadacitinib
IL-23 inhibitor
JAK inhibitor
Regulatory Update
Patients On Biologics
Clinicians
Why This Matters
An FDA approval of Skyrizi for subcutaneous induction could affect treatment options and access for people with Crohn’s disease. Corporate moves (acquisition, guidance) can influence drug availability, pricing, and company focus on IBD therapies.
Who Should Pay Attention
Patients with Crohn’s disease, clinicians treating IBD, people on or considering biologic therapy, and researchers/advocates tracking IBD drug approvals and access.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
AbbVie’s quarterly release highlights recent business and regulatory milestones relevant to IBD: Skyrizi (risankizumab) received FDA approval for a subcutaneous induction regimen in Crohn’s disease. This is a regulatory/label update reported in the company’s financial announcement, not a clinical trial report.
The piece also lists AbbVie products (Skyrizi, Rinvoq, Botox, Vraylar) and corporate actions (acquisition of Apogee Therapeutics, raised EPS guidance, dividend increase). It does not provide clinical details about the Skyrizi approval (such as eligible patients, dosing specifics, or trial data).
If you’re following treatment options, this signals a new FDA-approved dosing/administration pathway for an existing IBD drug, but clinical discussions with a gastroenterologist are needed to understand whether it applies to an individual’s care.
Keep In Mind
This is a business/earnings article summarizing AbbVie’s quarterly financial results and regulatory news. It does not provide clinical trial data or specific prescribing information—refer to FDA announcements or product labeling and discuss with a clinician for medical implications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationgrafa.com
AuthorsIsaac Francis
Indexed viaGoogle News
Source typeWeb article
PublishedOct 30, 2026, 1:15 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance? - TradingView
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - TradingView
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...